Macrogen, Inc.

KOSDAQ:A038290 Stock Report

Market Cap: ₩160.4b

Macrogen Valuation

Is A038290 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A038290 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A038290 (₩16070) is trading below our estimate of fair value (₩131949.03)

Significantly Below Fair Value: A038290 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A038290?

Key metric: As A038290 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A038290. This is calculated by dividing A038290's market cap by their current revenue.
What is A038290's PS Ratio?
PS Ratio1.2x
Sales₩131.73b
Market Cap₩160.36b

Price to Sales Ratio vs Peers

How does A038290's PS Ratio compare to its peers?

The above table shows the PS ratio for A038290 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16.9x
A278650 HLB bioStepLtd
3.7xn/a₩181.9b
A268600 Cellivery Therapeutics
10.9xn/a₩244.9b
A445680 Curiox Biosystems
49.4xn/a₩281.7b
A039860 NanoEntek
3.6xn/a₩105.0b
A038290 Macrogen
1.2x16.9%₩160.4b

Price-To-Sales vs Peers: A038290 is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (18.9x).

Price to Sales Ratio vs Industry

How does A038290's PS Ratio compare vs other companies in the KR Life Sciences Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
A245620 Eone Diagnomics Genome Center
0.8xn/aUS$41.47m
A215380 WOOJUNG BIO
0.6xn/aUS$20.05m
No more companies available in this PS range
A038290 1.2xIndustry Avg. 3.7xNo. of Companies7PS048121620+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A038290 is good value based on its Price-To-Sales Ratio (1.2x) compared to the KR Life Sciences industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is A038290's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A038290 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio2.1x

Price-To-Sales vs Fair Ratio: A038290 is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩513.9b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩19,910.00

7D

-0.7%

1Y

-34.6%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

7D

-4.8%

1Y

n/a

Medy-Tox

₩867.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩128,800.00

7D

2.1%

1Y

-41.2%